- Cabaletta Bio press release ( NASDAQ: CABA ): Q3 GAAP EPS of -$0.39 beats by $0.09 .
- As of September 30, 2022, Cabaletta had cash, cash equivalents and investments of $85.9 million, compared to $122.2 million as of December 31, 2021.
- Research and development expenses were $8.2 million for the three months ended September 30, 2022, compared to $8.2 million for the same period in 2021.
- General and administrative expenses were $3.6 million for the three months ended September 30, 2022, compared to $3.4 million for the same period in 2021.
For further details see:
Cabaletta Bio GAAP EPS of -$0.39 beats by $0.09